SEMAGLUTIDE (Glucagon-Like Peptide-1 (GLP-1))
• CAS number: 910463-68-2
• Molecular Weight: 4113.64 g/mol
• Formula: C187H291N45O59
SEMAGLUTIDE by DEUS MEDICAL®
SEMAGLUTIDE (Glucagon-Like Peptide-1 (GLP-1))
Overview
SEMAGLUTIDE is an agonist of the Glucagon-Like Peptide 1 receptor. It is used in the treatment of Type 2 diabetes. SEMAGLUTIDE is manufactured as 5mg/vial injections which contain Glucagon-Like Peptide-1 (GLP-1) 5mg and excipients.
SEMAGLUTIDE Mechanism of Action
SEMAGLUTIDE acts on the GLP-1 receptor to exert its effects. Once it binds to this receptor, a cascade of events is set in motion which results in the increased production of Insulin, inhibition of glucagon and delay of gastric emptying. The secreted insulin helps to mop up glucose and achieve blood sugar control. It has an advantage over other insulin secretagogues in that they have a lower risk of causing hypoglycemia.
SEMAGLUTIDE Dosage
As directed by the physician.
SEMAGLUTIDE Side Effects
Hypoglycemia, redness or inflammation at the injection site, nausea, vomiting, pancreas or gall bladder disease.
SEMAGLUTIDE Interactions
Beta-blockers, diabetes medications.
✓ Glucagon-Like Peptide-1 (GLP-1) . . . 5mg
✓ Excipients . . . . . . . . . . . . . . . . . . . . . q.s
BECOME A PARTNER
We are offering a diverse range of pharmaceutical products, which are available only from an authorized resellers. Our highly-regarded partners are comprised of industry experts who share our values and commitment. Our goal is to strengthen our network of prestigious professionals who strive to deliver great quality products.
We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.